Latest Biotech News

The biopharma sector continues to experience substantial workforce reductions in 2025, with 62 layoff rounds reported in the third quarter alone—nearly matching the 64 rounds recorded in each of...

Singapore-based Nanyang Biologics has entered a $1.5 billion business combination agreement with Nasdaq-listed RF Acquisition Corp II to facilitate its public listing. The company is building a...

The U.S. Food and Drug Administration greenlit new generic versions of mifepristone, the medical abortion pill, including Evita Solutions' product deemed bioequivalent to the original Mifeprex....

Major pharmaceutical companies Bristol Myers Squibb, Takeda, and Astex have joined forces to pool proprietary structural biology data sets for training OpenFold3, an AI platform dedicated to drug...

Cartography Biosciences closed a $67 million Series B financing round supporting their pipeline development of bispecific and multispecific T-cell engaging antibodies targeting novel and...

Researchers have developed CRISP, a cutting-edge computational framework enabling prediction of drug-induced perturbation responses at single-cell resolution across previously untested cell types....

Angelini Pharma has secured development and commercialization rights from Sovargen for SVG-105, an antisense oligonucleotide candidate targeting intractable epilepsy, through a $550 million...

The U.S. FDA convened a public listening session engaging industry experts from GeneVentiv Therapeutics, Viralgen, and others to discuss leveraging prior knowledge for accelerated cell and gene...

Foundation Medicine awarded a grant to My Style Matters and HYPE to support the Community Outreach for Detection and Education (CODE) initiative, aiming to increase biomarker testing access in...

Jazz Pharmaceuticals and Roche received FDA approval for their combination therapy of Zepzelca (lurbinectedin) and Tecentriq (atezolizumab) as a first-line maintenance treatment in extensive-stage...

Layoff rounds in the biopharma industry remain consistent across the first three quarters of 2025, with 190 rounds nearly matching 2024’s total of 192. Major companies such as Novo Nordisk and...

Singapore-based Nanyang Biologics announced a $1.5 billion business combination agreement with Nasdaq-listed RF Acquisition Corp II to go public. NYB is building a hybrid drug discovery platform...

The FDA approved a new generic version of the medical abortion pill mifepristone, marketed by Evita Solutions LLC, validating bioequivalence to the original product Mifeprex. This decision comes...

The biopharma sector witnessed major AI-driven innovations with projects like OpenFold3, where Bristol Myers Squibb, Takeda, and Astex are combining proprietary structural datasets to enhance drug...

Recent studies have advanced cancer understanding and treatment: Jazz-Roche's FDA-cleared combination targets lung cancer maintenance; PLK1 inhibition boosts gemcitabine-induced apoptosis in...

Large-scale genetic analyses yielded the largest human metabolism map linking genetic variants to blood metabolites across ancestries, revealing regulators of lipid metabolism and disease risk...

AI innovations are reshaping healthcare: AI expedites diagnosis and treatment triage for injured soldiers in Ukraine, optimizing evacuation workflows in complex environments. Concerns around...

Despite market pressures, biopharma financing maintains significant activity through 2025. Year-to-date, $47.1 billion has been raised, albeit down from 2024 peaks, primarily due to diminished...

Recent studies spotlight advances in enzyme applications: Near-infrared spectroscopy streamlines quantitation of polysorbate surfactants critical to biologic formulations, addressing challenges in...

The U.S. Food and Drug Administration granted expedited approval to the combination of Jazz Pharmaceuticals' Zepzelca (lurbinectedin) and Roche's Tecentriq (atezolizumab) as a first-line...